Progress, Potential, and Possibilities Podcast / Show · 2026-05-22 · 29 min
Send us Fan Mail Most autoimmune drugs suppress the immune system broadly - but what if you could selectively remove the antibodies actually causing disease? That’s exactly what VYVGART is doing, and it may fundamentally change how we treat conditions like myasthenia gravis and CIDP. Dr. Luc Truyen, M.D., Ph.D., is Chief Medical Officer at argenx ( ), where he leads the company’s global clinical development and medical strategy across a rapidly advancing portfolio of immunology and neuromuscular therapies. A neurologist by training, Dr. Truyen brings more than two decades of experience in drug development, with a particular focus on neuroscience, neuroimmunology, and complex CNS disorders. Before joining argenx in 2021, he spent over 20 years at Johnson & Johnson and its pharmaceutical division Janssen Pharmaceuticals, where he held multiple senior leadership roles. Most notably, Dr. Truyen served as Global Head of Development for Neuroscience at Janssen, overseeing early- and late-stage pipelines spanning mood disorders, schizophrenia, and neurodegenerative and neuroinflammatory diseases.
Other episodes covering the same guests and topics, from across The B2B Podcast Index.
Building the Internet of Medicine: How AI Could Transform Children's Healthcare | Dr. Timothy Chou - Founder, Pediatric Moonshot92 / 100Inside the Global Biotech Ecosystem - Where Innovation Goes Next | Sara Jane Demy - Founder and CEO, Demy-ColtonReversing Cellular Age: The Scientist Who Helped Create iPS Cells Reveals What’s Next - Dr. Koji Tanabe, Ph.D. - Founder and CEO, I Peace Inc.The End of High Cholesterol? The First Oral PCSK9 Drug Could Change Heart Medicine Forever - Dr. Norman Lepor, MD - Founder and Director, National Heart InstituteThe Hidden Heart Risk: Amgen’s Dr. Paul Burton on the Future of Preventing Heart Attacks - Dr. Paul Burton, M.D., Ph.D., F.A.C.C., M.R.C.S., F.R.C.P. - Senior Vice President and Chief Medical Officer - Amgen
